Valuation: Mymetics Corporation

Market Cap 439K 380K 356K 325K 611K 41.85M 621K 4.17M 1.64M 20.95M 1.65M 1.61M 69.88M P/E 2021
-1.86x
P/E 2022 -1.77x
Enterprise Value 72.12M 62.5M 58.51M 53.39M 100M 6.88B 102M 686M 269M 3.44B 271M 265M 11.49B EV / Sales 2021
177x
EV / Sales 2022 78x
Free-Float
99.88%
Yield 2021 *
-
Yield 2022 -
1 day+45.45%
1 week+1,066,566.67%
Current month+1,066,566.67%
1 month+1,066,566.67%
3 months+1,066,566.67%
6 months+1,066,566.67%
Current year+1,066,566.67%
Current year 0
Extreme 0.0003
3.2
1 year 0
Extreme 0.0003
3.2
3 years 0
Extreme 0.0003
26.2
5 years 0
Extreme 0.0003
230
10 years 0
Extreme 0.0003
380
Manager TitleAgeSince
Chief Executive Officer 58 18/11/2012
Change 5-day change 1-year change 3-year change Capi.($)
+45.45%+1,066,566.67%+1,066,566.67%-88.97% 45
-0.70%+13.34%+75.61%+103.83% 70.85B
-2.35%+2.88%+35.39%+64.72% 55.41B
-1.62%+34.25%+17.43%+491.04% 29.43B
-1.35%+11.37%+53.04%+6.32% 24.12B
0.00%+1.59%-15.06%-13.21% 23.31B
+0.05%+6.12%+46.81%-21.81% 18.37B
+9.77%+20.16%+260.17%+472.38% 16.99B
-0.76%+6.75%+30.08%+619.18% 16.1B
-3.08%-8.34%+37.21%+138.52% 13.12B
Average +4.53%+352.67%+106,710.74%+177.20% 26.77B
Weighted average by Cap. -0.56%+350.76%+56.08%+166.79%

Financials

2021 2022
Net sales 430K 373K 349K 318K 599K 41.01M 609K 4.09M 1.6M 20.53M 1.61M 1.58M 68.49M 1.03M 891K 834K 761K 1.43M 98.05M 1.46M 9.78M 3.83M 49.08M 3.86M 3.78M 164M
Net income -4.73M -4.1M -3.84M -3.5M -6.59M -451M -6.7M -44.99M -17.63M -226M -17.76M -17.37M -753M -4.8M -4.16M -3.9M -3.56M -6.69M -458M -6.81M -45.71M -17.91M -229M -18.04M -17.65M -765M
Net Debt 67.1M 58.15M 54.44M 49.67M 93.47M 6.4B 95.04M 638M 250M 3.2B 252M 246M 10.69B 71.68M 62.12M 58.16M 53.06M 99.86M 6.84B 102M 682M 267M 3.42B 269M 263M 11.42B
Logo Mymetics Corporation
Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.
Employees
-
  1. Stock Market
  2. Stocks
  3. MYMX Stock